Additionally, the use of multiple ErbB receptors for cell proliferation and survival in tumour cells and the synergistic transforming effects of EGFR and ErbB2 lead to the hypothesis that targeting both the EGFR and ErbB2 catalytic domains simultaneously through dual EGFR/ErbB2 inhibition would have superior therapeutic effects relative to single-agent treatment for cancer.10 Here, ERBB2 is linked to cancer.